Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate for the treatment of Sjögren’s Syndrome, a serious autoimmune disease. +Get the most important news from Switzerland in your inbox In the phase III trials Neptunus-1 and Neptunus-2, the therapy reduced disease activity in patients, a statement said today. The data will now be presented at a medical congress and forwarded to health authorities worldwide. Ianalumab has the potential to become the only targeted treatment for patients with Sjögren's Syndrome, according to Novartis. According to experts, the product could bring the group more than CHF1 billion ($1.24 billion) per year in the future. Ianalumab (VAY736) is a next-generation human antibody that could treat several B-cell-related diseases, including the aforementioned Sjögren's Syndrome, but also immune thrombocytopenia (PTI) and systemic lupus erythematosus (SLE). The therapy is the result of a ...
Full story here
Are you the author?
SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC).
Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.
Previous post
See more for 3.) Swissinfo Business and Economy
Next post
Tags:
Featured,
newsletter
